Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Real-world effectiveness of drugs newly approved in Japan on survival in patients with advanced gastric cancer.
Authors
Toru Kadono
Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan;
Toru Kadono , Satoru Iwasa , Hidekazu Hirano , Hirokazu Shoji , Natsuko Okita Okita , Atsuo Takashima , Ken Kato
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 322)
DOI
10.1200/JCO.2023.41.4_suppl.322
Abstract #
322
Poster Bd #
D3
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Real-world comparison of treatment outcomes between advanced esophagogastric junction adenocarcinoma and gastric adenocarcinoma.
First Author: Toru Kadono
Poster
2022 ASCO Gastrointestinal Cancers Symposium
REVIVE study: A prospective observational study in chemotherapy (CTx) after nivolumab (NIVO) therapy for advanced gastric cancer (AGC).
First Author: Tomohiro Matsushima
Poster
2021 Gastrointestinal Cancers Symposium
Angiogenesis-related factors associated with nivolumab efficacy in patients with advanced gastric cancer after refractory or intolerant to ramucirumab-based therapy.
First Author: Yuki Matsubara
Poster
2020 Gastrointestinal Cancers Symposium
Retrospective analysis for efficacy and safety of nivolumab in advanced gastric cancer patients (pts) with malignant ascites.
First Author: Akinori Sugaya